Exclusive distribution agreement marks Nanox’s entry into the Peruvian market
Rhea-AI Summary
Nanox (NASDAQ:NNOX) signed an exclusive distribution agreement with Top Med to deploy its Nanox.ARC imaging system and platform in Peru under a capex model.
Initial plans call for six Nanox.ARC systems, pending required permits, with a pilot phase followed by a possible broader rollout.
Positive
- Exclusive distribution agreement secures Nanox.ARC and platform access in Peru
- Initial deployment plan for six Nanox.ARC systems under a capex model
- Top Med handles approvals, marketing, installation, maintenance, training, and support
- Pilot phase allows validation in Peru’s local operating environment before expansion
- Nanox.ARC is FDA-cleared and CE marked multi-source digital tomosynthesis
- Nanox.ARC targets lower cost and reduced radiation dose versus traditional CT
Negative
- Deployment contingent on regulatory approvals and required permits in Peru
- Exclusive distribution subject to commercial milestones being achieved
- Broader rollout only potential following initial pilot phase results
- Top Med is a recently established entity, still early in operations
News Market Reaction – NNOX
On the day this news was published, NNOX declined 1.54%, reflecting a mild negative market reaction. Argus tracked a trough of -6.2% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $128.39M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 04 | U.S. distribution deal | Positive | +8.1% | NuvioDx distribution agreement to deploy Nanox.ARC across U.S. clinical sites. |
| Apr 23 | U.S. distribution deal | Positive | -14.3% | Radiology Oncology Systems agreement to expand Nanox.ARC adoption in U.S. |
| Apr 20 | Large U.S. deployment | Positive | -24.4% | Commercial agreement with Howard to deploy 300 Nanox.ARC systems over three years. |
| Apr 20 | Q4 2025 earnings | Negative | -24.4% | Q4 2025 results with $3.7M revenue and $33.4M net loss plus impairment. |
| Apr 16 | Product design award | Positive | +4.6% | Nanox.ARC X wins 2026 Red Dot Award for Product Design. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent commercial and partnership announcements often produced volatile and sometimes contrary reactions, with both strong gains and steep declines following seemingly positive deals.
Over the last few months, Nanox reported recurring distribution and commercial agreements for its Nanox.ARC systems in the U.S., including a 300-system deal with Howard Technology Solutions and additional channel partnerships. Market reactions ranged from -24.39% to +8.09% on these news items. The company also posted Q4 2025 results with continued losses and secured product recognition via a Red Dot design award. Today’s Peru distribution agreement extends this commercial rollout pattern into Latin America.
Key Terms
capex model financial
fda-cleared regulatory
ce marked regulatory
digital tomosynthesis medical
teleradiology medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Initial deployment is expected to include six Nanox.ARC systems under a capex model
PETACH TIKVA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging Ltd. (“Nanox”, or the “Company” NASDAQ: NNOX), a leader in innovative medical imaging technology, today announced a distribution agreement with Top Med SAC (“Top Med”) to deploy the Nanox.ARC system and related services in Peru.
Under the agreement, Nanox appointed Top Med as its exclusive distributor of the Nanox.ARC system and Nanox platform in Peru, subject to commercial milestones and regulatory requirements. The agreement is structured as a capex model and includes an expected initial deployment of six Nanox.ARC systems, subject to receipt of the required permits.
Top Med will be responsible for obtaining required regulatory approvals and for marketing, installation, maintenance, training, and ongoing technical support of deployed systems. The agreement includes an initial pilot phase in the local operating environment, followed by a potentially broader commercial rollout.
The agreement establishes Nanox’s presence in Peru, where access to diagnostic imaging services remains unevenly distributed across regions.
Erez Meltzer, Chief Executive Officer and Acting Chairman of Nanox, said: “This agreement reflects the pace of our commercial execution in 2026. Peru represents an important market for expanding access to advanced imaging, and Top Med brings the operational depth to support deployment at scale.”
Luis Ramos, Chief Executive Officer of Top Med, said: “We are committed to improving access to diagnostic imaging in Peru, where access is variable and there is significant unmet need. We see the Nanox.ARC as an important tool in achieving that. We look forward to working with Nanox to bring advanced imaging capabilities to more patients across Peru.”
The Nanox.ARC is an FDA-cleared and CE marked, multi-source digital tomosynthesis system that makes 3D imaging accessible in more clinical settings, at a lower cost and reduced radiation dose compared to traditional CT.
Top Med is a recently established entity that shares common ownership with TopRad LLC (“TopRad”), a U.S.-based teleradiology provider. Nanox currently collaborates with TopRad in connection with teleradiology services. TopRad is not a party to the distribution agreement described herein. TopRad’s experience in the U.S. market can provide a strong foundation as Top Med begins operations in Peru.
About Nanox
Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by delivering an integrated, end-to-end medical imaging and healthcare services platform.
Nanox combines affordable imaging hardware, advanced AI-based solutions, cloud-based software, access to remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care.
Nanox’s vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes.
The Nanox ecosystem includes Nanox.ARC, a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability; Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT, which combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery.
By integrating imaging technology, AI, cloud infrastructure, clinical expertise, a marketplace, and health information technology, Nanox seeks to lower barriers to adoption, improve utilization, and advance preventive care worldwide. For more information, please visit www.nanox.vision
Forward-Looking Statements
This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements that are not historical facts contained in this press release are forward-looking statements. Such statements include, but are not limited to, any statements relating to the initiation, timing, progress and results of the Company’s research and development, manufacturing, and commercialization activities with respect to its X-ray source technology and the Nanox.ARC, the ability to realize the expected benefits of its recent acquisitions and the projected business prospects of the Company and the acquired companies. In some cases, you can identify forward-looking statements by terminology such as “can,” “might,” “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “should,” “could,” “expect,” “predict,” “potential,” or the negative of these terms or other similar expressions. Forward-looking statements are based on information the Company has when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Factors that could cause actual results to differ materially from those currently anticipated include: risks related to (i) Nanox’s ability to complete development of the Nanox System; (ii) Nanox’s ability to successfully demonstrate the feasibility of its technology for commercial applications; (iii) Nanox’s history of recurring losses and negative cash flows from operating activities, significant future commitments and the uncertainty regarding the adequacy of Nanox’s liquidity to pursue its complete business objectives, and substantial doubt regarding its ability to continue as a going concern; (iv) Nanox’s expectations regarding the necessity of, timing of filing for, and receipt and maintenance of, regulatory clearances or approvals regarding its technology, the Nanox.ARC and Nanox.CLOUD from regulatory agencies worldwide and its ongoing compliance with applicable quality standards and regulatory requirements; (v) Nanox’s ability to realize the anticipated benefits of the acquisitions, which may be affected by, among other things, competition, brand recognition, the ability of the acquired companies to grow and manage growth profitably and retain their key employees; (vi) Nanox’s ability to enter into and maintain commercially reasonable arrangements with third-party manufacturers and suppliers to manufacture the Nanox.ARC; (vii) the market acceptance of the Nanox System and the proposed pay-per-scan business model; (viii) Nanox’s expectations regarding collaborations with third-parties and their potential benefits; (ix) Nanox’s ability to conduct business globally; (x) changes in global, political, economic, business, competitive, market and regulatory forces; (xi) risks related to the current war between Israel and Hamas and any worsening of the situation in Israel; (xii) risks related to business interruptions resulting from the COVID-19 pandemic or similar public health crises, among other things; and (xiii) potential litigation associated with our transactions.
For a discussion of other risks and uncertainties, and other important factors, any of which could cause Nanox’s actual results to differ from those contained in the Forward-Looking Statements, see the section titled “Risk Factors” in Nanox’s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings with the U.S. Securities and Exchange Commission. The reader should not place undue reliance on any forward-looking statements included in this press release. Except as required by law, Nanox undertakes no obligation to update publicly any forward-looking statements after the date of this press release to conform these statements to actual results or to changes in the Company’s expectations.
Contacts
Media Contact:
Ben Shannon
ICR Healthcare
NanoxPR@icrinc.com
Investor Contact:
Mike Cavanaugh
ICR Healthcare
mike.cavanaugh@icrhealthcare.com
